NCT03758339View on ClinicalTrials.gov

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 30, 2017

Primary Completion Date

January 30, 2018

Study Completion Date

January 30, 2018

Conditions
Healthy
Interventions
DRUG

tucatinib

Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

Sponsors
All Listed Sponsors
lead

Cascadian Therapeutics Inc.

INDUSTRY

NCT03758339 - A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants | Biotech Hunter | Biotech Hunter